CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
443.91MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.5500xvs all stocks
52-Week Change
-14.31%vs all stocks
Market Capitalization
443.91MUSDvs all stocks (USD)
Enterprise Value
324.75MUSDvs all stocks (USD)
Forward P/E
-7.36xvs Biotechnology peers
Price to Book (MRQ)
4.12xvs Biotechnology peers
Enterprise to EBITDA
-3.78xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-48.74%vs Biotechnology peers
Return on Equity (TTM)
-81.73%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-85.82MUSDvs all stocks (USD)
Net Income (TTM)
-81.48MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-73.48MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-43.71MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Jun 30, 2025Operating Income
-79.89MUSDvs all stocks (USD)
Pre-tax Income
-74.41MUSDFY2025 · Jun 30, 2025Net Income
-74.41MUSDFY2025 · Jun 30, 2025EBIT
-79.89MUSDFY2025 · Jun 30, 2025EBITDA (Income Statement)
-79.86MUSDFY2025 · Jun 30, 2025Research & Development
61.53MUSDFY2025 · Jun 30, 2025Selling, General & Administrative
18.37MUSDFY2025 · Jun 30, 2025Non-operating Interest Income
5.48MUSDFY2025 · Jun 30, 2025EPS (Basic)
-0.9800USDFY2025 · Jun 30, 2025EPS (Diluted)
-0.9800USDFY2025 · Jun 30, 2025Basic Shares Outstanding
76.00MSharesFY2025 · Jun 30, 2025Diluted Shares Outstanding
76.00MSharesFY2025 · Jun 30, 2025Net Income from Continuing Operations
-74.41MUSDFY2025 · Jun 30, 2025Operating Cash Flow
-65.31MUSDFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
94.11MUSDFY2025 · Jun 30, 2025Income Tax Paid
0.00USDFY2025 · Jun 30, 2025Interest Paid
0.00USDFY2025 · Jun 30, 2025Starting Profit (CF Statement)
-74.41MUSDFY2025 · Jun 30, 2025Depreciation & Amortization
31.00KUSDFY2025 · Jun 30, 2025Stock-based Compensation
7.12MUSDFY2025 · Jun 30, 2025Other Non-cash Items
532.00KUSDFY2025 · Jun 30, 2025Change in Accounts Payable (CF)
1.42MUSDFY2025 · Jun 30, 2025Purchase of Investments
-128.14MUSDFY2025 · Jun 30, 2025Sale of Investments
113.60MUSDFY2025 · Jun 30, 2025Net Investing Cash Flow
-14.54MUSDFY2025 · Jun 30, 2025Other Financing Charges
-1.06MUSDFY2025 · Jun 30, 2025Net Financing Cash Flow
85.34MUSDFY2025 · Jun 30, 2025Shares Outstanding
96.29MSharesUpdated Jul 19, 2026Float Shares
66.01MSharesUpdated Jul 19, 2026Shares Short
16.41MSharesUpdated Jul 19, 2026Short Ratio
6.05daysvs all stocks
Short % of Shares Outstanding
25.65%vs all stocks
% Held by Insiders
10.15%vs all stocks
% Held by Institutions
90.58%vs all stocks
Total Cash (MRQ)
120.27MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.25USDUpdated Jul 19, 2026Total Debt (MRQ)
1.11MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0095xvs Biotechnology peers
Current Ratio (MRQ)
15.84xvs Biotechnology peers
Book Value per Share (MRQ)
1.12USDUpdated Jul 19, 2026Total Assets
175.49MUSDvs all stocks (USD)
Total Current Assets
171.15MUSDFY2025 · Jun 30, 2025Total Liabilities
13.36MUSDFY2025 · Jun 30, 2025Total Non-current Assets
4.34MUSDFY2025 · Jun 30, 2025Total Non-current Liabilities
1.45MUSDFY2025 · Jun 30, 2025Total Current Liabilities
11.91MUSDFY2025 · Jun 30, 2025Cash
5.05MUSDFY2025 · Jun 30, 2025Cash Equivalents
89.06MUSDFY2025 · Jun 30, 2025Cash & Cash Equivalents
94.11MUSDFY2025 · Jun 30, 2025Other Short-term Investments
73.75MUSDFY2025 · Jun 30, 2025Accounts Payable
5.81MUSDFY2025 · Jun 30, 2025Short-term Debt
632.00KUSDFY2025 · Jun 30, 2025Long-term Debt
983.00KUSDFY2025 · Jun 30, 2025Common Stock (Book)
87.00KUSDFY2025 · Jun 30, 2025Retained Earnings
-403.86MUSDFY2025 · Jun 30, 2025Total Shareholders' Equity
162.13MUSDvs all stocks (USD)
52-Week Low
1.07USDUpdated Jul 19, 202652-Week High
11.46USDUpdated Jul 19, 202652-Week Change
-14.31%vs all stocks
Beta
0.5500xvs all stocks
50-Day MA
4.16USDUpdated Jul 19, 2026200-Day MA
4.91USDUpdated Jul 19, 2026Avg 10-Day Volume
1.58MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.15MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.8500USDUpdated Jul 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.70
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Clover Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Varex Imaging Corporation
Tier 1ProductionApproval-Gated PipelineRule
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jw Pharmaceutical Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Delcath Systems Inc.
Tier 1ProductionApproval-Gated PipelineRule
Baotou Dongbao Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Haisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pacific Biosciences of California, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangxi Synergy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hubei Goto Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule